Lyrica Cr
(Pregabalin)Lyrica Cr Prescribing Information
Warnings and Precautions, Respiratory Depression | 4/2020 |
LYRICA CR is indicated for the management of:
• Neuropathic pain associated with diabetic peripheral neuropathy• Postherpetic neuralgia
Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.
• LYRICA CR should be administered once daily after an evening meal. It should be swallowed whole and should not be split, crushed, or chewed.• Dosing recommendations for LYRICA CR:
Indication | Dosing Regimen | Initial Dose | Maximum Dose |
|---|---|---|---|
DPN Pain | Single dose per day | 165 mg/day | 330 mg/day within 1 week. |
PHN | Single dose per day | 165 mg/day | 330 mg/day within 1 week. Maximum dose of 660 mg/day. |
• Conversion from LYRICA Capsules or Oral Solution to LYRICA CR: See full prescribing information.• Dose modification recommended in patients with renal impairment.
Extended-release tablets: 82.5 mg, 165 mg, and 330 mg
LYRICA CR Tablets | |
|---|---|
Tablet Strength (mg) | Tablet Description |
82.5 mg | Light blue, film-coated, almond-shaped tablet debossed with Pfizer on 1 side and PGN 82.5 on the other side |
165 mg | Beige, film-coated, almond-shaped tablet debossed with Pfizer on 1 side and PGN 165 on the other side |
330 mg | Rose, film-coated, almond-shaped tablet debossed with Pfizer on 1 side and PGN 330 on the other side |
• Pregnancy: May cause fetal harm. Advise of potential risk to the fetus.• Lactation: Breastfeeding is not recommended.
LYRICA CR is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy